NEW ORLEANS – Among the best therapies for some varieties of lymphoma and leukemia has been a drug known as ibrutinib, made by AbbVie. When it hit the market in 2013, the drug revolutionized the therapy of those cancers and represented a significant step ahead from chemotherapy and another medicine on the time.
However analysis introduced on the American Society of Hematology assembly in New Orleans advised {that a} second-generation drug known as zanubrutinib from BeiGene is about to unseat ibrutinib as “the king on the block” for the therapy of persistent lymphocytic leukemia, mentioned Catherine Diefenbach, medical director of the lymphoma program on the NYU Langone’s Perlmutter Most cancers Middle.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
GET STARTED